Table 1.
Select Patient and Tumor Characteristics
| Characteristic | No Radiation Pneumonitis (n = 85) | Symptomatic Radiation Pneumonitis (n = 8) | P value |
|---|---|---|---|
| Age, years | |||
| Median | 73.5 | 72.4 | 0.56† |
| Range | 10.1–89.2 | 50.4–79.8 | |
| Tumor size, cma | |||
| Median | 1.8 | 3.4 | 0.002† |
| Range | 0.6–4.0 | 1.7–5.3 | |
| T stagea | |||
| T1 (%) | 73 (94.8%) | 2 (33.3%) | 0.001 |
| T2 (%) | 4 (5.2%) | 4 (66.7%) | |
| Radiation Dose | |||
| 50/5 (%) | 57 (67.1%) | 6 (75.0%) | 0.004 |
| 48/4 (%) | 26 (30.1%) | 0 (0.0%) | |
| 60/5–8 (%) | 2 (2.4%) | 2 (25.0%) | |
| Treatment year | |||
| 2010 | 1 (1.2%) | 0 (0.0%) | 0.86 |
| 2011 | 7 (8.2%) | 0 (0.0%) | |
| 2012 | 9 (10.6%) | 0 (0.0%) | |
| 2013 | 10 (11.8%) | 0 (0.0%) | |
| 2014 | 7 (8.2%) | 1 (12.5%) | |
| 2015 | 19 (22.4%) | 2 (25.0%) | |
| 2016 | 24 (28.2%) | 4 (50.0%) | |
| 2017 | 8 (9.4%) | 1 (12.5%) | |
| Race | |||
| Black (%) | 9 (10.6%) | 0 (0.0%) | 1.000 |
| White (%) | 74 (87.1%) | 8 (100.0%) | |
| Other (%) | 2 (2.4%) | 0 (0.0%) | |
| Sex | |||
| Female (%) | 49 (57.6%) | 6 (75.0%) | 0.46 |
| Male (%) | 36 (42.4%) | 2 (25.0%) | |
| Smoking status (missing = 11) | |||
| Not smoking (%) | 23 (30.2%) | 4 (66.7%) | 1.000 |
| Current smoker (%) | 53 (69.7%) | 2 (33.3%) | |
| Pack years | |||
| Median | 40 | 27.5 | 0.25 |
| Range | 0–180.0 | 0–82.5 | |
| ECOG Performance status | |||
| 0 (%) | 25 (29.4%) | 2 (25.0%) | 0.82 |
| 1 (%) | 43 (50.6%) | 4 (50.0%) | |
| 2 (%) | 15 (17.7%) | 2 (25.0%) | |
| 3 (%) | 2 (2.4%) | 0 (0.0%) | |
| Sitea | |||
| RUL (%) | 21 (26.9%) | 0 | 0.06 |
| RML (%) | 5 (6.4%) | 0 | |
| RLL (%) | 23 (29.5%) | 2 (33.3%) | |
| LUL (%) | 18 (23.1%) | 1 (16.7%) | |
| LLL (%) | 11 (14.1%) | 2 (33.3%) | |
| Liver (%) | 0 (0.0%) | 1 (16.7%) | |
| Histology | |||
| Adenocarcinoma (%) | 36 (42.4%) | 3 (37.5%) | 0.87 |
| Squamous cell carcinoma (%) | 25 (29.4%) | 3 (37.5%) | |
| No biopsy (%) | 9 (10.6%) | 1 (12.5%) | |
| Metastatic non-lung primary (%) | 6 (7.1%) | 1 (12.5%) | |
| NOS/other (%) | 8 (9.4%) | 0 (0.0%) | |
| SCLC (%) | 1 (1.2%) | 0 (0.0%) | |
| Prior Radiation to Lung | |||
| Yes, SBRT (%) | 11 (12.9%) | 1 (12.5%) | 0.27 |
| Yes, CCRT (%) | 6 (7.1%) | 2 (25.0%) | |
| Yes, Mantle field (%) | 1 (1.2%) | 0 (0.0%) | |
| No (%) | 67 (78.8%) | 5 (62.5%) | |
| Two lesions treated simultaneously | |||
| Yes (%) | 8 (11.5%) | 2 (25.0%) | 0.21 |
| No (%) | 77 (88.5%) | 6 (75.0%) | |
Abbreviations: SBRT Stereotactic Body Radiation Therapy, CCRT Conventionally fractionated concurrent chemoradiation therapy. Symptomatic Radiation Pneumonitis = RTOG G3+ or CTCAE G2+ RP
Bolded P-values indicate statistical significance
All P-values are from Fishers test unless otherwise noted
aValues omit synchronously treated lesions due to multiple values per patient
†P-values from Wilcoxon Rank Sum tests